Since TFEB amplification is associated with a more aggressive clinical manifestation and poor outcomes for renal cell carcinoma, efforts have been made to accurately diagnose patients with TFEB translocations for improved patient management (141). This evidence concerns the gene TFEB and renal cell carcinoma.